Start - Analyst Group

Latest news

Equity research report

2025-03-24

Pharma Equity Group Q4-24

Comment

2025-03-20

Comment on PEG’s Year-End Report for 2024

Equity research report

2025-03-06

STENOCARE Q4-24

Comment

2025-02-27

Comment on STENOCARE’s Q4-report Report 2024

Comment

2025-01-22

Comment on the Outcome of STENOCARE’s Conditional Rights Issue

Comment

2024-12-20

Comment on STENOCARE’s Announcement of a Conditional Rights Issue of up to DKK 20.2m

Comment

2024-12-17

Comment on STENOCARE’s Approval for a new Medical Cannabis CBD100 oil

Comment

2024-12-13

Comment on Pharma Equity Group’s New Execution Strategy

Comment

2024-12-02

Comment on that STENOCARE’s Astrum Oil has been Approved for Sales in Norway

Comment

2024-11-27

Comment on STENOCARE Shifting Strategy to Focus on Trading and Exit from Production

Comment

2024-11-20

Comment on the Danish Health Minister’s Decision to Propose a Permanent Legalization of Medical Cannabis

Equity research report

2024-11-19

Pharma Equity Group Q3-24

Comment

2024-11-15

Comment on PEG’s Q3 Report for 2024

Equity research report

2024-11-11

STENOCARE Q3-24

Comment

2024-11-06

Comment on STENOCARE’s Q3-Report 2024

Comment

2024-10-23

Comment on Pharma Equity Group’s obtained patent protection in Japan for RNX-051

Comment

2024-10-14

Comment on STENOCARE’s Updated Guidance for 2024

Comment

2024-10-07

Comment on Pharma Equity Group’s Directed Share Issue to a Premium

Equity research report

2024-09-05

ODI Pharma

Comment

2024-08-29

Comment on ODI Pharma’s Quarterly Report

Equity research report

2024-08-29

STENOCARE Q2-24

Comment

2024-08-22

Comment on STENOCARE’s Q2-report Report 2024

Video

2024-08-20

Interview with Pharma Equity Group’s CEO Thomas Kaas Selsø

Equity research report

2024-08-20

Pharma Equity Group Q2-24

Comment

2024-08-16

Comment on PEG’s Q2 Report for 2024

Comment

2024-06-26

Comment on ODI Pharma’s Strategic Market Entry to Switzerland

Equity research report

2024-06-05

ODI Pharma Q1-24

Equity research report

2024-05-08

STENOCARE Q1-24

Equity research report

2024-05-06

ODI Pharma

Video

2024-05-06

Interview with ODI Pharma’s Chairman of the Board Volker Wiederrich

Comment

2024-05-02

Comment on STENOCARE’s Q1-report Report 2024

Comment

2024-04-05

Comment on Pharma Equity Group’s Positive Final Results From the Phase II Trial of the Drug Candidate RNX-051

Equity research report

2024-03-27

Movinn Q4-23

Comment

2024-03-22

Comment on Movinn’s Annual Report

Equity research report

2024-03-22

Pharma Equity Group Q4-23

Comment

2023-12-14

Comment on STENOCARE Expanding in Australia

Comment

2023-11-23

Comment on STENOCARE Adding a new Product in Australia

Equity research report

2023-11-14

STENOCARE Q3-23

Equity research report

2023-11-10

Movinn Q3-23

Comment

2023-11-09

Comment on STENOCARE’s Q3-report

Comment

2023-11-07

Comment on STENOCARE’s Updated Guidance and One-off Return of Products from Norway

Comment

2023-11-03

Analyst Group Comments on Movinn’s Q3-report

Equity research report

2023-10-23

OrderYOYO Q3-23

Comment

2023-10-18

Analyst Group Comments on OrderYOYO’s Q3-23 Trading Update

Equity research report

2023-09-28

RTX

Comment

2023-09-22

Analyst Group Comments on Movinn Expands to Ludvika

Comment

2023-09-19

Comment on STENOCARE’s Market Update

Equity research report

2023-09-11

Brain+ H2-23

Comment

2023-09-01

Analyst Group Comments on Brain+’s Semi-Annual Report 2023

Equity research report

2023-09-01

Movinn Q2-23

Equity research report

2023-08-30

OrderYOYO

Comment

2023-08-25

Comment on Movinn’s Q2-report

Equity research report

2023-08-24

STENOCARE Q2-23

Comment

2023-08-22

Analyst Group Comments on OrderYOYO’s H1-23 Report

Comment

2023-07-18

Analyst Group Comments on OrderYOYO’s Q2-23 Trading Update

Equity research report

2023-06-28

STENOCARE

Comment

2023-06-20

Comment on STENOCARE’s Q1-Report 2023

Comment

2023-05-30

Comment on STENOCARE Launching an IT-platform for Online Clinics

Comment

2023-05-16

Comment on STENOCARE’s Rights Issue

Equity research report

2023-05-11

Brain+ Q1-23

Equity research report

2023-05-11

Movinn Q1-23

Comment

2023-05-04

Analyst Groups Comment on Movinn’s Q1-report

Comment

2023-05-02

Analyst Group Comments on Brain+’s Annual Report 2022

Comment

2023-04-17

Analyst Group Comments on OrderYOYO’s Q1 Performance and Acquisition of Kingfood

Equity research report

2023-04-12

Movinn

Equity research report

2023-03-29

OrderYOYO

Comment

2023-03-21

Analyst Group Comments on OrderYOYO’s Annual Report 2022

Equity research report

2023-03-02

STENOCARE Q4-22

Equity research report

2022-12-12

STENOCARE

Equity research report

2022-10-27

OrderYOYO

Comment

2022-08-30

Analyst Group’s comment on Trophy Games acquisition and management appointment

Equity research report

2022-08-22

Trophy Games

Comment

2022-08-17

Analyst Group’s comment on Trophy Games H1 report

Comment

2022-06-20

Comment on OrderYOYO’s merger with German app smart

Comment

2022-05-16

Analyst Groups comment on Trophy Games announcement

Equity research report

2022-04-07

WirTek

Equity research report

2022-04-07

CirChem

Equity research report

2022-03-30

OrderYOYO Q4-21

Equity research report

2022-03-30

Anima Group

Equity research report

2022-03-23

Transfer Group

Equity Research Report on Pharma Equity Group

Equity Research Report on Stenocare

Equity Research Report on Pharma Equity Group

Equity Research Report on Stenocare

Equity Research Report on ODI Pharma

Equity Research Report on Pharma Equity Group

Equity Research Report on Movinn

Equity Research Report on OrderYOYO

Independent Analysis on RTX

Equity Research Report on Brain+

Equity Research Report on OrderYOYO

Equity Research Report on STENOCARE

Equity Research Report on Brain+

Equity Research Report on OrderYOYO

Equity Research Report on OrderYOYO

Equity Research Report on OrderYOYO

Equity Research Report on Trophy Games

Equity Research Report on OrderYOYO

Latest news

Pharma Equity Group Q4-24

Comment on PEG’s Year-End Report for 2024

STENOCARE Q4-24

Comment on STENOCARE’s Q4-report Report 2024

Comment on the Outcome of STENOCARE’s Conditional Rights Issue

Comment on STENOCARE’s Announcement of a Conditional Rights Issue of up to DKK 20.2m

Comment on STENOCARE’s Approval for a new Medical Cannabis CBD100 oil

Comment on Pharma Equity Group’s New Execution Strategy

Comment on that STENOCARE’s Astrum Oil has been Approved for Sales in Norway

Comment on STENOCARE Shifting Strategy to Focus on Trading and Exit from Production

Comment on the Danish Health Minister’s Decision to Propose a Permanent Legalization of Medical Cannabis

Pharma Equity Group Q3-24

Comment on PEG’s Q3 Report for 2024

STENOCARE Q3-24

Comment on STENOCARE’s Q3-Report 2024

Comment on Pharma Equity Group’s obtained patent protection in Japan for RNX-051

Comment on STENOCARE’s Updated Guidance for 2024

Comment on Pharma Equity Group’s Directed Share Issue to a Premium

ODI Pharma

Comment on ODI Pharma’s Quarterly Report

STENOCARE Q2-24

Comment on STENOCARE’s Q2-report Report 2024

Interview with Pharma Equity Group’s CEO Thomas Kaas Selsø

Pharma Equity Group Q2-24

Comment on PEG’s Q2 Report for 2024

Comment on ODI Pharma’s Strategic Market Entry to Switzerland

ODI Pharma Q1-24

STENOCARE Q1-24

ODI Pharma

Interview with ODI Pharma’s Chairman of the Board Volker Wiederrich

Comment on STENOCARE’s Q1-report Report 2024

Comment on Pharma Equity Group’s Positive Final Results From the Phase II Trial of the Drug Candidate RNX-051

Movinn Q4-23

Comment on Movinn’s Annual Report

Pharma Equity Group Q4-23

Comment on STENOCARE Expanding in Australia

Comment on STENOCARE Adding a new Product in Australia

STENOCARE Q3-23

Movinn Q3-23

Comment on STENOCARE’s Q3-report

Comment on STENOCARE’s Updated Guidance and One-off Return of Products from Norway

Analyst Group Comments on Movinn’s Q3-report

OrderYOYO Q3-23

Analyst Group Comments on OrderYOYO’s Q3-23 Trading Update

RTX

Analyst Group Comments on Movinn Expands to Ludvika

Comment on STENOCARE’s Market Update

Brain+ H2-23

Analyst Group Comments on Brain+’s Semi-Annual Report 2023

Movinn Q2-23

OrderYOYO

Comment on Movinn’s Q2-report

STENOCARE Q2-23

Analyst Group Comments on OrderYOYO’s H1-23 Report

Analyst Group Comments on OrderYOYO’s Q2-23 Trading Update

STENOCARE

Comment on STENOCARE’s Q1-Report 2023

Comment on STENOCARE Launching an IT-platform for Online Clinics

Comment on STENOCARE’s Rights Issue

Brain+ Q1-23

Movinn Q1-23